Chart reviews: Make these changes to prevent payer mistakes
Detailed consent statements are recommended, even for repeated treatments.
Related Articles
The NMIBC Treatment Landscape: Emerging Evidence and Real-World Impact
Experts take a deep dive into the latest advancement, exploring groundbreaking clinical trial data, real-world evidence of newly approved therapies, and ongoing research shaping the…
DISCOVER THE IMPACT OF GEMTESA: A Selective β3-Adrenergic Agonist Now Approved for Effective OAB Treatment in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia (BPH)
Already Registered? Login here. REGISTER NOW Already registered?
SBRT may offer a safe alternative to CFRT after prostatectomy
Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
Administering onabotA: Improving patient comfort and easing anxiety
An expert walks through specific actions that urologists and their teams can take before, during, and after the procedure.
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Nearly 60% of patients taking vibegron remained on treatment at 1 year.
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic
“The use of telemedicine is heavily dependent on supportive legislature,” write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Published data support safety, efficacy of vaginal insert for SUI
Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.
Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer
ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.
Long-term data point to durable efficacy of Optilume for urethral strictures
The freedom from re-intervention rate was 71%.
MRI and focal therapy may enable men on AS to safely delay surgery or radiation
Use of focal therapy was shown to prolong the duration of active surveillance.